Clinical Trials Directory

Trials / Completed

CompletedNCT00044746

Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections

An Open-label, Randomized Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabetic Inpatients

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
314 (actual)
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.

Conditions

Interventions

TypeNameDescription
DRUGPiperacillin/Tazobactam

Timeline

Start date
2000-10-01
Primary completion
2003-01-01
Completion
2003-01-01
First posted
2002-09-06
Last updated
2013-02-08

Source: ClinicalTrials.gov record NCT00044746. Inclusion in this directory is not an endorsement.